Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewML 337
说明： Selective negative allosteric modulator of mGlu3 receptors
化学名： [2-Fluoro-4-[2-(4-methoxyphenyl)ethynyl]phenyl][(3R)-3-hydroxy-1-piperidinyl]methanone
纯度： ≥98% (HPLC)
生物活性 for ML 337
ML 337 is a selective negative allosteric modulator of mGlu3 (IC50 = 593 nM). Displays no activity at mGlu1, mGlu2 or mGlu4-8 at concentrations up to 30 μM. Brain penetrant.
化合物库 for ML 337
ML 337 is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。
技术数据 for ML 337
| 分子量 | 353.39 |
| 公式 | C21H20FNO3 |
| 储存 | Store at +4°C |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 1443118-44-2 |
| PubChem ID | 60204017 |
| InChI Key | QBCRLDPMQHPGIM-QGZVFWFLSA-N |
| Smiles | O=C(N1CCC[C@@H](O)C1)C(C(F)=C2)=CC=C2C#CC3=CC=C(OC)C=C3 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for ML 337
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| DMSO | 35.34 | 100 | |
| ethanol | 7.07 | 20 |
制备储备液 for ML 337
以下数据基于产品分子量 353.39。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.83 mL | 14.15 mL | 28.3 mL |
| 5 mM | 0.57 mL | 2.83 mL | 5.66 mL |
| 10 mM | 0.28 mL | 1.41 mL | 2.83 mL |
| 50 mM | 0.06 mL | 0.28 mL | 0.57 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for ML 337
参考文献 for ML 337
参考文献是支持产品生物活性的出版物。
Wenthur et al (2013) Discovery of (R)-(2-fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-hydroxypiperidin-1-yl)methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM). J.Med.Chem. 56 5208 PMID: 23718281
If you know of a relevant reference for ML 337, please let us know.
关键词: ML 337, ML 337 supplier, ML337, mglu, metabotropic, glutamate, mGlu3, receptors, negative, allosteric, modulators, NAMs, selective, Glutamate, (Metabotropic), Group, II, Receptors, 4982, Tocris Bioscience
ML 337 的评论
目前没有该产品的评论。 Be the first to review ML 337 and earn rewards!
Have you used ML 337?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.